Article
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.
Cancer research communications - 1 Jul 2025
Eisenmann Eric D, Swords Ronan, Huang Ying, Orwick Shelley, Buelow Daelynn, Abbott Nicole, Phelps Mitch, Zeidner Joshua, Foster Matthew C, Lin Tara L, Baer Maria R, Madanat Yazan F, Kovacsovics Tibor, Redner Robert, Al-Mansour Zeina, Bhatnagar Bhavana, Stefanos Mona, Martycz Molly, Druggan Franchesca, Chen Timothy L, Yocum Ashley O, Borate Uma, Druker Brian J, Burd Amy, Levine Ross L, Byrd John C, Baker Sharyn D, Mims Alice S
Abstract excerpt
PURPOSE: Older patients who have acute myeloid leukemia (AML) with mutant TP53 and/or complex karyotype have a dismal prognosis and lack treatment options. Having previously demonstrated that TP-0903, a multikinase inhibitor, has compelling preclinical activity in drug-resistant AML, including TP53-mutated AML, we evaluated the clinical activity of TP-0903 in combination with decitabine. PATIENTS AND METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.